The goal of the study was to determine the early diagnostical potential of cardiovascular disease-associated microRNAs for prediction of small-for-gestational-age (SGA) and fetal growth restriction (FGR) without preeclampsia (PE). The whole peripheral venous blood samples were collected within 10 to 13 weeks of gestation from singleton Caucasian pregnancies within the period November 2012 to March 2020. The case-control retrospective study, nested in a cohort, involved all pregnancies diagnosed with SGA (n = 37) or FGR (n = 82) without PE and 80 appropriate-for-gestational age (AGA) pregnancies selected with regard to equality of sample storage time. Gene expression of 29 cardiovascular disease-associated microRNAs was assessed using real-time RT-PCR. Upregulation of miR-16-5p, miR-20a-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, and miR-195-5p was observed in SGA or FGR pregnancies at 10.0% false positive rate (FPR). Upregulation of miR-1-3p, miR-20b-5p, miR-126-3p, miR-130b-3p, and miR-499a-5p was observed in SGA pregnancies only at 10.0% FPR. Upregulation of miR-145-5p, miR-342-3p, and miR-574-3p was detected in FGR pregnancies at 10.0% FPR. The combination of four microRNA biomarkers (miR-1-3p, miR-20a-5p, miR-146a-5p, and miR-181a-5p) was able to identify 75.68% SGA pregnancies at 10.0% FPR in early stages of gestation. The detection rate of SGA pregnancies without PE increased 4.67-fold (75.68% vs. 16.22%) when compared with the routine first-trimester screening for PE and/or FGR based on the criteria of the Fetal Medicine Foundation. The combination of seven microRNA biomarkers (miR-16-5p, miR-20a-5p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-342-3p, and miR-574-3p) was able to identify 42.68% FGR pregnancies at 10.0% FPR in early stages of gestation. The detection rate of FGR pregnancies without PE increased 1.52-fold (42.68% vs. 28.05%) when compared with the routine first-trimester screening for PE and/or FGR based on the criteria of the Fetal Medicine Foundation. Cardiovascular disease-associated microRNAs represent promising early biomarkers with very suitable predictive potential for SGA or FGR without PE to be implemented into the routine screening programs.

Department of Molecular Biology and Cell Pathology 3rd Faculty of Medicine Charles University 100 00 Prague Czech Republic

Institute for the Care of the Mother and Child 3rd Faculty of Medicine Charles University 147 00 Prague Czech Republic

Zobrazit více v PubMed

De Onis M., Habicht J.P. Anthropometric reference data for international use: Recommendations from a World Health Organization Expert Committee. Am. J. Clin. Nutr. 1996;64:650–658. doi: 10.1093/ajcn/64.4.650. PubMed DOI

WHO . Physical Status: The Use and Interpretation of Anthropometry. Vol. 854. World Health Organization; Geneva, Switzerland: 1995. pp. 1–452. Report of a WHO Expert Committee. PubMed

American College of Obstetricians and Gynecologists Committee on Practice Bulletins—Obstetrics, Society for Maternal-Fetal Medicine Publications Committee. Fetal Growth Restriction: ACOG Practice Bulletin, Number 227. Obstet. Gynecol. 2021;137:e16–e28. doi: 10.1097/AOG.0000000000004251. PubMed DOI

Lees C.C., Stampalija T., Baschat A., da Silva Costa F., Ferrazzi E., Figueras F., Hecher K., Kingdom J., Poon L.C., Salomon L.J., et al. ISUOG Practice Guidelines: Diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet. Gynecol. 2020;56:298–312. doi: 10.1002/uog.22134. PubMed DOI

Jackson M.R., Walsh A.J., Morrow R.J., Mullen J.B., Lye S.J., Ritchie J.W. Reduced placental villous tree elaboration in small-for-gestational-age pregnancies: Relationship with umbilical artery Doppler waveforms. Am. J. Obstet. Gynecol. 1995;172:518–525. doi: 10.1016/0002-9378(95)90566-9. PubMed DOI

Van Oppenraaij R.H., Bergen N.E., Duvekot J.J., de Krijger R.R., Hop Ir W.C., Steegers E.A., Exalto N. Placental vascularization in early onset small for gestational age and preeclampsia. Reprod. Sci. 2011;18:586–593. doi: 10.1177/1933719110396231. PubMed DOI

Widdows K., O’Malley A., O’Neill B., Kingdom J., Gillan J., Ansari T. Altered placental development in pregnancies resulting in sudden infant death syndrome (SIDS) Early Hum. Dev. 2012;88:805–811. doi: 10.1016/j.earlhumdev.2012.05.006. PubMed DOI

Zhao X.J., Xu J.P., Li B., Qi J.L., Ping S.M., Zhu H.Y., Liu B.N. Relationship between placental pathology and small-for-gestational age neonates. Zhonghua Bing Li Xue Za Zhi. 2012;41:737–741. PubMed

Ganer Herman H., Barber E., Gasnier R., Gindes L., Bar J., Schreiber L., Kovo M. Placental pathology and neonatal outcome in small for gestational age pregnancies with and without abnormal umbilical artery Doppler flow. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018;222:52–56. doi: 10.1016/j.ejogrb.2018.01.009. PubMed DOI

Gordijn S.J., Beune I.M., Thilaganathan B., Papageorghiou A., Baschat A.A., Baker P.N., Silver R.M., Wynia K., Ganzevoort W. Consensus definition of fetal growth restriction: A Delphi procedure. Ultrasound Obstet. Gynecol. 2016;48:333–339. doi: 10.1002/uog.15884. PubMed DOI

Tan M.Y., Syngelaki A., Poon L.C., Rolnik D.L., O’Gorman N., Delgado J.L., Akolekar R., Konstantinidou L., Tsavdaridou M., Galeva S., et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation. Ultrasound Obstet. Gynecol. 2018;52:186–195. doi: 10.1002/uog.19112. PubMed DOI

O’Gorman N., Wright D., Poon L.C., Rolnik D.L., Syngelaki A., de Alvarado M., Carbone I.F., Dutemeyer V., Fiolna M., Frick A., et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation: Comparison with NI-CE guidelines and ACOG recommendations. Ultrasound Obstet. Gynecol. 2017;49:756–760. doi: 10.1002/uog.17455. PubMed DOI

O’Gorman N., Wright D., Syngelaki A., Akolekar R., Wright A., Poon L.C., Nicolaides K.H. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am. J. Obstet. Gynecol. 2016;214:103.e1–103.e12. doi: 10.1016/j.ajog.2015.08.034. PubMed DOI

The Fetal Medicine Foundation Stratification of Pregnancy Management 11–13 Weeks’ Gestation. [(accessed on 4 November 2021)]. Available online: www.courses.fetalmedicine.com/fmf/show/861?locale=en.

Mazer Zumaeta A., Wright A., Syngelaki A., Maritsa V.A., Da Silva A.B., Nicolaides K.H. Screening for pre-eclampsia at 11-13 weeks’ gestation: Use of pregnancy-associated plasma protein-A, placental growth factor or both. Ultrasound Obstet. Gynecol. 2020;56:400–407. doi: 10.1002/uog.22093. PubMed DOI

Papastefanou I., Wright D., Syngelaki A., Souretis K., Chrysanthopoulou E., Nicolaides K.H. Competing-risks model for prediction of small-for-gestational-age neonate from biophysical and biochemical markers at 11–13 weeks’ gestation. Ultrasound Obstet. Gynecol. 2021;57:52–61. doi: 10.1002/uog.23523. PubMed DOI

Romero Infante X.C., Uriel M., Porras Ramírez A., Rincón Franco S. Comparison of preeclampsia and fetal growth restriction screenings at first trimester in a high-risk population. J. Obstet. Gynaecol. Res. 2021;47:765–773. doi: 10.1111/jog.14605. PubMed DOI

Rolnik D.L., Wright D., Poon L.C., O’Gorman N., Syngelaki A., de Paco Matallana C., Akolekar R., Cicero S., Janga D., Singh M., et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N. Engl. J. Med. 2017;377:613–622. doi: 10.1056/NEJMoa1704559. PubMed DOI

Wright D., Poon L.C., Rolnik D.L., Syngelaki A., Delgado J.L., Vojtassakova D., de Alvarado M., Kapeti E., Rehal A., Pazos A., et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: Influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am. J. Obstet. Gynecol. 2017;217:685.e1–685.e5. doi: 10.1016/j.ajog.2017.08.110. PubMed DOI

Tan M.Y., Poon L.C., Rolnik D.L., Syngelaki A., de Paco Matallana C., Akolekar R., Cicero S., Janga D., Singh M., Molina F.S., et al. Prediction and prevention of small-for-gestational-age neonates: Evidence from SPREE and ASPRE. Ultrasound Obstet. Gynecol. 2018;52:52–59. doi: 10.1002/uog.19077. PubMed DOI

ACOG Committee Opinion No. 743. Low-Dose Aspirin Use During Pregnancy. Obstet. Gynecol. 2018;132:e44–e52. doi: 10.1097/AOG.0000000000002708. PubMed DOI

Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:1–2. doi: 10.1186/gb-2002-3-7-research0034. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Hympanova L., Krofta L. Gestational hypertension, preeclampsia and intrauterine growth restriction induce dysregulation of cardiovascular and cerebrovascular disease associated microRNAs in maternal whole peripheral blood. Thromb. Res. 2016;137:126–140. doi: 10.1016/j.thromres.2015.11.032. PubMed DOI

Andersen C.L., Jensen J.L., Ørntoft T.F. Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64:5245–5250. doi: 10.1158/0008-5472.CAN-04-0496. PubMed DOI

Benjamini Y., Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R Stat. Soc. Ser. B. 1995;57:289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x. DOI

Haynes W. Benjamini–Hochberg Method. In: Dubitzky W., Wolkenhauer O., Cho K.H., Yokota H., editors. Encyclopedia of Systems Biology. Springer; New York, NY, USA: 2013.

Kim S.H., MacIntyre D.A., Binkhamis R., Cook J., Sykes L., Bennett P.R., Terzidou V. Maternal plasma miRNAs as potential biomarkers for detecting risk of small-for-gestational-age births. EBioMedicine. 2020;62:103145. doi: 10.1016/j.ebiom.2020.103145. PubMed DOI PMC

Pei J., Li Y., Min Z., Dong Q., Ruan J., Wu J., Hua X. MiR-590-3p and its targets VEGF, PIGF, and MMP9 in early, middle, and late pregnancy: Their longitudinal changes and correlations with risk of fetal growth restriction. Ir. J. Med. Sci. 2021 doi: 10.1007/s11845-021-02664-6. Epub ahead of print. PubMed DOI

Hromadnikova I., Dvorakova L., Kotlabova K., Krofta L. The Prediction of Gestational Hypertension, Preeclampsia and Fetal Growth Restriction via the First Trimester Screening of Plasma Exosomal C19MC microRNAs. Int. J. Mol. Sci. 2019;20:2972. doi: 10.3390/ijms20122972. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Ivankova K., Krofta L. First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR. PLoS ONE. 2017;12:e0171756. doi: 10.1371/journal.pone.0171756. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Krofta L. Cardiovascular-Disease Associated MicroRNA Dysregulation during the First Trimester of Gestation in Women with Chronic Hypertension and Normotensive Women Subsequently Developing Gestational Hypertension or Preeclampsia with or without Fetal Growth Restriction. Biomedicines. 2022;10:256. PubMed PMC

Trajkovski M., Hausser J., Soutschek J., Bhat B., Akin A., Zavolan M., Heim M.H., Stoffel M. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–653. doi: 10.1038/nature10112. PubMed DOI

Sun X., Sit A., Feinberg M.W. Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc. Med. 2014;24:105–112. doi: 10.1016/j.tcm.2013.09.002. PubMed DOI PMC

Hulsmans M., Sinnaeve P., Van der Schueren B., Mathieu C., Janssens S., Holvoet P. Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. J. Clin. Endocrinol. Metab. 2012;97:e1213–e1218. doi: 10.1210/jc.2012-1008. PubMed DOI

Lozano-Bartolomé J., Llauradó G., Portero-Otin M., Altuna-Coy A., Rojo-Martínez G., Vendrell J., Jorba R., Rodríguez-Gallego E., Chacón M.R. Altered Expression of miR-181a-5p and miR-23a-3p Is Associated with Obesity and TNFα-Induced Insulin Resistance. J. Clin. Endocrinol. Metab. 2018;103:1447–1458. doi: 10.1210/jc.2017-01909. PubMed DOI

Wang L., Xu L., Xu M., Liu G., Xing J., Sun C., Ding H. Obesity-Associated MiR-342-3p Promotes Adipogenesis of Mesenchymal Stem Cells by Suppressing CtBP2 and Releasing C/EBPα from CtBP2 Binding. Cell Physiol. Biochem. 2015;35:2285–2298. doi: 10.1159/000374032. PubMed DOI

He A., Zhu L., Gupta N., Chang Y., Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol. Endocrinol. 2007;21:2785–2794. doi: 10.1210/me.2007-0167. PubMed DOI

Elmén J., Lindow M., Silahtaroglu A., Bak M., Christensen M., Lind-Thomsen A., Hedtjärn M., Hansen J.B., Hansen H.F., Straarup E.M., et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008;36:1153–1162. doi: 10.1093/nar/gkm1113. PubMed DOI PMC

Elmén J., Lindow M., Schütz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjärn M., Hansen H.F., Berger U., et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452:896–899. doi: 10.1038/nature06783. PubMed DOI

Fish J.E., Santoro M.M., Morton S.U., Yu S., Yeh R.F., Wythe J.D., Ivey K.N., Bruneau B.G., Stainier D.Y., Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell. 2008;15:272–284. doi: 10.1016/j.devcel.2008.07.008. PubMed DOI PMC

Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., Richardson J.A., Bassel-Duby R., Olson E.N. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell. 2008;15:261–271. doi: 10.1016/j.devcel.2008.07.002. PubMed DOI PMC

Chen T., Huang Z., Wang L., Wang Y., Wu F., Meng S., Wang C. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocytes/macrophages. Cardiovasc. Res. 2009;83:131–139. doi: 10.1093/cvr/cvp121. PubMed DOI

Marquart T.J., Allen R.M., Ory D.S., Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc. Natl. Acad. Sci. USA. 2010;107:12228–12232. doi: 10.1073/pnas.1005191107. PubMed DOI PMC

Najafi-Shoushtari S.H., Kristo F., Li Y., Shioda T., Cohen D.E., Gerszten R.E., Näär A.M. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328:1566–1569. doi: 10.1126/science.1189123. PubMed DOI PMC

Rayner K.J., Suárez Y., Dávalos A., Parathath S., Fitzgerald M.L., Tamehiro N., Fisher E.A., Moore K.J., Fernández-Hernando C. Mir-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328:1570–1573. doi: 10.1126/science.1189862. PubMed DOI PMC

Zampetaki A., Kiechl S., Drozdov I., Willeit P., Mayr U., Prokopi M., Mayr A., Weger S., Oberhollenzer F., Bonora E., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 2010;107:810–817. doi: 10.1161/CIRCRESAHA.110.226357. PubMed DOI

Zhao H., Guan J., Lee H.M., Sui Y., He L., Siu J.J., Tse P.P., Tong P.C., Lai F.M., Chan J.C. Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through β-cell deficit and islet amyloid deposition. Pancreas. 2010;39:843–846. doi: 10.1097/MPA.0b013e3181d12613. PubMed DOI

Kida K., Nakajima M., Mohri T., Oda Y., Takagi S., Fukami T., Yokoi T. PPARα is regulated by miR-21 and miR-27b in human liver. Pharm Res. 2011;28:2467–2476. doi: 10.1007/s11095-011-0473-y. PubMed DOI

Pullen T.J., da Silva Xavier G., Kelsey G., Rutter G.A. miR-29a and miR-29b contribute to pancreatic β-cell-specific silencing of monocarboxylate transporter 1 (Mct1) Mol. Cell Biol. 2011;31:3182–3194. doi: 10.1128/MCB.01433-10. PubMed DOI PMC

Rayner K.J., Esau C.C., Hussain F.N., McDaniel A.L., Marshall S.M., van Gils J.M., Ray T.D., Sheedy F.J., Goedeke L., Liu X., et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404–407. doi: 10.1038/nature10486. PubMed DOI PMC

Ryu H.S., Park S.Y., Ma D., Zhang J., Lee W. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS ONE. 2011;6:e17343. doi: 10.1371/annotation/2faafaa7-e359-4711-af5b-3597c705388d. PubMed DOI PMC

Yang K., He Y.S., Wang X.Q., Lu L., Chen Q.J., Liu J., Sun Z., Shen W.F. MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting Toll-like receptor 4. FEBS Lett. 2011;585:854–860. doi: 10.1016/j.febslet.2011.02.009. PubMed DOI

Zhong D., Zhang Y., Zeng Y.J., Gao M., Wu G.Z., Hu C.J., Huang G., He F.T. MicroRNA-613 represses lipogenesis in HepG2 cells by downregulating LXRα. Lipids Health Dis. 2013;12:32. doi: 10.1186/1476-511X-12-32. PubMed DOI PMC

Zhong D., Huang G., Zhang Y., Zeng Y., Xu Z., Zhao Y., He X., He F. MicroRNA-1 and microRNA-206 suppress LXRα-induced lipogenesis in hepatocytes. Cell Signal. 2013;25:1429–1437. doi: 10.1016/j.cellsig.2013.03.003. PubMed DOI

Van Rooij E., Sutherland L.B., Qi X., Richardson J.A., Hill J., Olson E.N. Control of stress-dependent cardiac growth and gene expression bz a microRNA. Science. 2007;316:575–579. doi: 10.1126/science.1139089. PubMed DOI

Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., Galuppo P., Just S., Rottbauer W., Frantz S., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980–984. doi: 10.1038/nature07511. PubMed DOI

Callis T.E., Pandya K., Seok H.Y., Tang R.H., Tatsuguchi M., Huang Z.P., Chen J.F., Deng Z., Gunn B., Shumate J., et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Investig. 2009;119:2772–2786. doi: 10.1172/JCI36154. PubMed DOI PMC

Elia L., Quintavalle M., Zhang J., Contu R., Cossu L., Latronico M.V., Peterson K.L., Indolfi C., Catalucci D., Chen J., et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: Correlates with human disease. Cell Death Differ. 2009;16:1590–1598. doi: 10.1038/cdd.2009.153. PubMed DOI PMC

Xin M., Small E.M., Sutherland L.B., Qi X., McAnally J., Plato C.F., Richardson J.A., Bassel-Duby R., Olson E.N. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23:2166–2178. doi: 10.1101/gad.1842409. PubMed DOI PMC

Li S., Zhu J., Zhang W., Chen Y., Zhang K., Popescu L.M. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation. 2011;124:175–184. doi: 10.1161/CIRCULATIONAHA.110.012237. PubMed DOI

Norata G.D., Pinna C., Zappella F., Elia L., Sala A., Condorelli G., Catapano A.L. MicroRNA 143-145 deficiency impairs vascular function. Int. J. Immunopathol. Pharmacol. 2012;25:467–474. doi: 10.1177/039463201202500216. PubMed DOI

O´Connell R.M., Taganov K.D., Boldin M.P., Cheng G., Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. USA. 2007;104:1604–1609. doi: 10.1073/pnas.0610731104. PubMed DOI PMC

Harris T.A., Yamakuchi M., Ferlito M., Mendell J.T., Lowenstein C.J. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl. Acad. Sci. USA. 2008;105:1516–1521. doi: 10.1073/pnas.0707493105. PubMed DOI PMC

Wang Y.S., Wang H.Y., Liao Y.C., Tsai P.C., Chen K.C., Cheng H.Y., Lin R.T., Juo S.H. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc. Res. 2012;95:517–526. doi: 10.1093/cvr/cvs223. PubMed DOI

Kong L., Zhu J., Han W., Jiang X., Xu M., Zhao Y., Dong Q., Pang Z., Guan Q., Gao L., et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol. 2011;48:61–69. doi: 10.1007/s00592-010-0226-0. PubMed DOI

Ji R., Cheng Y., Yue J., Yang J., Liu X., Chen H., Dean D.B., Zhang C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ. Res. 2007;100:1579–1588. doi: 10.1161/CIRCRESAHA.106.141986. PubMed DOI

Cordes K.R., Sheehy N.T., White M.P., Berry E.C., Morton S.U., Muth A.N., Lee T.H., Miano J.M., Ivey K.N., Srivastava D. miR-145 and miR-143 regulate smooth Musile cell fate and plasticity. Nature. 2009;460:705–710. doi: 10.1038/nature08195. PubMed DOI PMC

Raitoharju E., Lyytikäinen L.P., Levula M., Oksala N., Mennander A., Tarkka M., Klopp N., Illig T., Kähönen M., Karhunen P.J., et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis. 2011;219:211–217. doi: 10.1016/j.atherosclerosis.2011.07.020. PubMed DOI

Rayner K.J., Moore K.J. The plaque “micro” environment: microRNAs control the risk and the development of atherosclerosis. Curr. Atheroscler. Rep. 2012;14:413–421. doi: 10.1007/s11883-012-0272-x. PubMed DOI PMC

Zhu J., Chen T., Yang L., Li Z., Wong M.M., Zheng X., Pan X., Zhang L., Yan H. Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS ONE. 2012;7:e46551. doi: 10.1371/journal.pone.0046551. PubMed DOI PMC

Wei Y., Nazari-Jahantigh M., Neth P., Weber C., Schober A. MicroRNA-126, -145, and -155: A therapeutic triad in atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 2013;33:449–454. doi: 10.1161/ATVBAHA.112.300279. PubMed DOI

Poliseno L., Tuccoli A., Mariani L., Evangelista M., Citti L., Woods K., Mercatanti A., Hammond S., Rainaldi G. MicroRNAs modulate the angiogenic properties of HUVECs. Blood. 2006;108:3068–3071. doi: 10.1182/blood-2006-01-012369. PubMed DOI

Doebele C., Bonauer A., Fischer A., Scholz A., Reiss Y., Urbich C., Hofmann W.K., Zeiher A.M., Dimmeler S. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood. 2010;115:4944–4950. doi: 10.1182/blood-2010-01-264812. PubMed DOI

Grundmann S., Hans F.P., Kinniry S., Heinke J., Helbing T., Bluhm F., Sluijter J.P., Hoefer I., Pasterkamp G., Bode C., et al. MicroRNA-100 regulates neovascularization by suppression of mammalian target of rapamycin in endothelial and vascular smooth muscle cells. Circulation. 2011;123:999–1009. doi: 10.1161/CIRCULATIONAHA.110.000323. PubMed DOI

Cheng Y., Liu X., Yang J., Lin Y., Xu D.Z., Lu Q., Deitch E.A., Huo Y., Delphin E.S., Zhang C. MicroRNA-145, a novel smooth muscle cell phenotzpic marker and modulátor, controls vascular neointimal lesion formation. Circ. Res. 2009;105:158–166. doi: 10.1161/CIRCRESAHA.109.197517. PubMed DOI PMC

Zernecke A., Bidzhekov K., Noels H., Shagdarsuren E., Gan L., Denecke B., Hristov M., Köppel T., Jahantigh M.N., Lutgens E., et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal. 2009;2:ra81. doi: 10.1126/scisignal.2000610. PubMed DOI

Fichtlscherer S., De Rosa S., Fox H., Schwietz T., Fischer A., Liebetrau C., Weber M., Hamm C.W., Röxe T., Müller-Ardogan M., et al. Circulating microRNAs in patients with coronary artery disease. Circ. Res. 2010;107:677–684. doi: 10.1161/CIRCRESAHA.109.215566. PubMed DOI

Liu X., Cheng Y., Yang J., Xu L., Zhang C. Cell-specific effects of miR-221/222 in vessels: Molecular mechanism and therapeutic application. J. Mol. Cell Cardiol. 2012;52:245–255. doi: 10.1016/j.yjmcc.2011.11.008. PubMed DOI PMC

Olson E.N., Williams R.S. Calcineurin signaling and muscle remodeling. Cell. 2000;101:689–692. doi: 10.1016/S0092-8674(00)80880-6. PubMed DOI

Van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., Richardson J.A., Olson E.N. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart silure. Proc. Natl. Acad. Sci. USA. 2006;103:18255–18260. doi: 10.1073/pnas.0608791103. PubMed DOI PMC

Ikeda S., Kong S.W., Lu J., Bisping E., Zhang H., Allen P.D., Golub T.R., Pieske B., Pu W.T. Altered microRNA expression in human heart disease. Physiol. Genom. 2007;31:367–373. doi: 10.1152/physiolgenomics.00144.2007. PubMed DOI

Liu N., Williams A.H., Kim Y., McAnally J., Bezprozvannaya S., Sutherland L.B., Richardson J.A., Bassel-Duby R., Olson E.N. An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc. Natl. Acad. Sci. USA. 2007;104:20844–20849. doi: 10.1073/pnas.0710558105. PubMed DOI PMC

Tatsuguchi M., Seok H.Y., Callis T.E., Thomson J.M., Chen J.F., Newman M., Rojas M., Hammond S.M., Wang D.Z. Expression of microRNAs is dramatically regulated during cardiomyocyte hypertrophy. J. Mol. Cell Cardiol. 2007;42:1137–1141. doi: 10.1016/j.yjmcc.2007.04.004. PubMed DOI PMC

Sucharov C., Bristow M.R., Port J.D. miRNA expression in the failing human heart: Functional correlates. J. Mol. Cell Cardiol. 2008;45:185–192. doi: 10.1016/j.yjmcc.2008.04.014. PubMed DOI PMC

Urbich C., Kuehbacher A., Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc. Res. 2008;79:581–588. doi: 10.1093/cvr/cvn156. PubMed DOI

Van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., Hill J.A., Olson E.N. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. USA. 2008;105:13027–13032. doi: 10.1073/pnas.0805038105. PubMed DOI PMC

Van Rooij E., Marshall W.S., Olson E.N. Toward microRNA-based therapeutics for heart disease: The sense in antisepse. Circ. Res. 2008;103:919–928. doi: 10.1161/CIRCRESAHA.108.183426. PubMed DOI PMC

Catalucci D., Gallo P., Condorelli G. MicroRNAs in cardiovascular biology and heart disease. Circ. Cardiovasc. Genet. 2009;2:402–408. doi: 10.1161/CIRCGENETICS.109.857425. PubMed DOI

Ikeda S., He A., Kong S.W., Lu J., Bejar R., Bodyak N., Lee K.H., Ma Q., Kang P.M., Golub T.R., et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol. Cell Biol. 2009;29:2193–2204. doi: 10.1128/MCB.01222-08. PubMed DOI PMC

Ji X., Takahashi R., Hiura Y., Hirokawa G., Fukushima Y., Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin. Chem. 2009;55:1944–1949. doi: 10.1373/clinchem.2009.125310. PubMed DOI

Lin Z., Murtaza I., Wang K., Jiao J., Gao J., Li P.F. miR-23a functions downstream of NFATc3 to regulace cardiac hypertrophy. Proc. Natl. Acad. Sci. USA. 2009;106:12103–12108. doi: 10.1073/pnas.0811371106. PubMed DOI PMC

Rane S., He M., Sayed D., Vashistha H., Malhotra A., Sadoshima J., Vatner D.E., Vatner S.F., Abdellatif M. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ. Res. 2009;104:879–886. doi: 10.1161/CIRCRESAHA.108.193102. PubMed DOI PMC

Roy S., Khanna S., Hussain S.R., Biswas S., Azad A., Rink C., Gnyawali S., Shilo S., Nuovo G.J., Sen C.K. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 2009;82:21–29. doi: 10.1093/cvr/cvp015. PubMed DOI PMC

Adachi T., Nakanishi M., Otsuka Y., Nishimura K., Hirokawa G., Goto Y., Nonogi H., Iwai N. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin. Chem. 2010;56:1183–1185. doi: 10.1373/clinchem.2010.144121. PubMed DOI

Ai J., Zhang R., Li Y., Pu J., Lu Y., Jiao J., Li K., Yu B., Li Z., Wang R., et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun. 2010;391:73–77. doi: 10.1016/j.bbrc.2009.11.005. PubMed DOI

Cheng Y., Tan N., Yang J., Liu X., Cao X., He P., Dong X., Qin S., Zhang C. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin. Sci. 2010;119:87–95. doi: 10.1042/CS20090645. PubMed DOI PMC

Corsten M.F., Dennert R., Jochems S., Kuznetsova T., Devaux Y., Hofstra L., Wagner D.R., Staessen J.A., Heymans S., Schroen B. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular dinase. Circ. Cardiovasc. Genet. 2010;3:499–506. doi: 10.1161/CIRCGENETICS.110.957415. PubMed DOI

D’Alessandra Y., Devanna P., Limana F., Straino S., Di Carlo A., Brambilla P.G., Rubino M., Carena M.C., Spazzafumo L., De Simone M., et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur. Heart J. 2010;31:2765–2773. doi: 10.1093/eurheartj/ehq167. PubMed DOI PMC

Fukushima Y., Nakanishi M., Nonogi H., Goto Y., Iwai N. Assessment of plasma Midas in congestive heart silure. Circ. J. 2010;75:336–340. doi: 10.1253/circj.CJ-10-0457. PubMed DOI

Song X.W., Li Q., Lin L., Wang X.C., Li D.F., Wang G.K., Ren A.J., Wang Y.R., Qin Y.W., Yuan W.J., et al. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. J. Cell Physiol. 2010;225:437–443. doi: 10.1002/jcp.22217. PubMed DOI

Rane S., He M., Sayed D., Yan L., Vatner D., Abdellatif M. An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p. Cell. Signal. 2010;22:1054–1062. doi: 10.1016/j.cellsig.2010.02.008. PubMed DOI PMC

Voellenkle C., van Rooij J., Cappuzzello C., Greco S., Arcelli D., Di Vito L., Melillo G., Rigolini R., Costa E., Crea F., et al. MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. Physiol. Genom. 2010;42:420–426. doi: 10.1152/physiolgenomics.00211.2009. PubMed DOI

Wang G.K., Zhu J.Q., Zhang J.T., Li Q., Li Y., He J., Qin Y.W., Jing Q. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur. Heart J. 2010;31:659–666. doi: 10.1093/eurheartj/ehq013. PubMed DOI

Gidlöf O., Andersson P., van der Pals J., Götberg M., Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology. 2011;118:217–226. doi: 10.1159/000328869. PubMed DOI

Shieh J.T., Huang Y., Gilmore J., Srivastava D. Elevated miR-499 levels blunt the cardiac stress response. PLoS ONE. 2011;6:e19481. doi: 10.1371/journal.pone.0019481. PubMed DOI PMC

Wang J.X., Jiao J.Q., Li Q., Long B., Wang K., Liu J.P., Li Y.R., Li P.F. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat. Med. 2011;17:71–78. doi: 10.1038/nm.2282. PubMed DOI

Zile M.R., Mehurg S.M., Arroyo J.E., Stroud R.E., Desantis S.M., Spinale F.G. Relationship between the tempoval profile of plasma microRNA and left ventricular remodeling in patients following myocardial infarction. Circ. Cardiovasc. Genet. 2011;4:614–619. doi: 10.1161/CIRCGENETICS.111.959841. PubMed DOI PMC

Long G., Wang F., Duan Q., Chen F., Yang S., Gong W., Wang Y., Chen C., Wang D.W. Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int. J. Biol. Sci. 2012;8:811–818. doi: 10.7150/ijbs.4439. PubMed DOI PMC

Ellis K.L., Cameron V.A., Troughton R.W., Frampton C.M., Ellmers L.J., Richards A.M. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur. J. Heart Fail. 2013;15:1138–1147. doi: 10.1093/eurjhf/hft078. PubMed DOI

Wei C., Kim I.K., Kumar S., Jayasinghe S., Hong N., Castoldi G., Catalucci D., Jones W.K., Gupta S. NF-κB mediated miR-26a regulation in cardiac fibrosis. J. Cell. Physiol. 2013;228:1433–1442. doi: 10.1002/jcp.24296. PubMed DOI

Beaumont J., López B., Hermida N., Schroen B., San José G., Heymans S., Valencia F., Gómez-Doblas J.J., De Teresa E., Díez J., et al. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation. Clin. Sci. 2014;126:497–506. doi: 10.1042/CS20130538. PubMed DOI

Wu J., Du K., Lu X. Elevated expressions of serum miR-15a, miR-16, and miR-17-5p are associated with acute ischemic stroke. Int. J. Clin. Exp. Med. 2015;8:21071–21079. PubMed PMC

Tiedt S., Prestel M., Malik R., Schieferdecker N., Duering M., Kautzky V., Stoycheva I., Böck J., Northoff B.H., Klein M., et al. RNA-Seq Identifies Circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as Potential Biomarkers for Acute Ischemic Stroke. Circ. Res. 2017;121:970–980. doi: 10.1161/CIRCRESAHA.117.311572. PubMed DOI

Li S.H., Chen L., Pang X.M., Su S.Y., Zhou X., Chen C.Y., Huang L.G., Li J.P., Liu J.L. Decreased miR-146a expression in acute ischemic stroke directly targets the Fbxl10 mRNA and is involved in modulating apoptosis. Neurochem. Int. 2017;107:156–167. doi: 10.1016/j.neuint.2017.01.011. PubMed DOI

Wu J., Fan C.L., Ma L.J., Liu T., Wang C., Song J.X., Lv Q.S., Pan H., Zhang C.N., Wang J.J. Distinctive expression signatures of serum microRNAs in ischaemic stroke and transient ischaemic attack patients. Thromb. Haemost. 2017;117:992–1001. PubMed

Zhu J., Yao K., Wang Q., Guo J., Shi H., Ma L., Liu H., Gao W., Zou Y., Ge J. Circulating miR-181a as a Potential Novel Biomarker for Diagnosis of Acute Myocardial Infarction. Cell Physiol. Biochem. 2016;40:1591–1602. doi: 10.1159/000453209. PubMed DOI

Brock M., Samillan V.J., Trenkmann M., Schwarzwald C., Ulrich S., Gay R.E., Gassmann M., Ostergaard L., Gay S., Speich R., et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur. Heart J. 2014;35:3203–3211. doi: 10.1093/eurheartj/ehs060. PubMed DOI

Deng B., Du J., Hu R., Wang A.P., Wu W.H., Hu C.P., Li Y.J., Li X.H. MicroRNA-103/107 is involved in hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by targeting HIF-1β. Life Sci. 2016;147:117–124. doi: 10.1016/j.lfs.2016.01.043. PubMed DOI

Hromadnikova I., Kotlabova K., Krofta L. A History of Preterm Delivery Is Associated with Aberrant Postpartal MicroRNA Expression Profiles in Mothers with an Absence of Other Pregnancy-Related Complications. Int. J. Mol. Sci. 2021;22:4033. doi: 10.3390/ijms22084033. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Dvorakova L., Krofta L. Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases. Int. J. Mol. Sci. 2020;21:2437. doi: 10.3390/ijms21072437. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Krofta L., Sirc J. Postnatal Expression Profile of MicroRNAs Associated with Cardiovascular Diseases in 3- to 11-Year-Old Preterm-Born Children. Biomedicines. 2021;9:727. doi: 10.3390/biomedicines9070727. PubMed DOI PMC

Hromadnikova I., Kotlabova K., Dvorakova L., Krofta L., Sirc J. Substantially Altered Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk. Cells. 2020;9:1557. PubMed PMC

Abnormal microRNA expression profile at early stages of gestation in pregnancies destined to develop placenta previa

First-trimester predictive models for adverse pregnancy outcomes-a base for implementation of strategies to prevent cardiovascular disease development

First-Trimester Screening for Miscarriage or Stillbirth-Prediction Model Based on MicroRNA Biomarkers

First-Trimester Screening for HELLP Syndrome-Prediction Model Based on MicroRNA Biomarkers and Maternal Clinical Characteristics

Novel First-Trimester Prediction Model for Any Type of Preterm Birth Occurring before 37 Gestational Weeks in the Absence of Other Pregnancy-Related Complications Based on Cardiovascular Disease-Associated MicroRNAs and Basic Maternal Clinical Characteristics

Cardiovascular Disease-Associated MicroRNAs as Novel Biomarkers of First-Trimester Screening for Gestational Diabetes Mellitus in the Absence of Other Pregnancy-Related Complications

First Trimester Prediction of Preterm Delivery in the Absence of Other Pregnancy-Related Complications Using Cardiovascular-Disease Associated MicroRNA Biomarkers